Therapeutic agent for fibromyalgia containing etanercept
US8729027B2 · kind B2 · utility
0Cited by
1References
3Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Jul 4, 2011 |
| Grant date | May 20, 2014 |
| Priority date | — |
| Expiry date | Jul 4, 2031 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P29/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed is a drug effective in the treatment of fibromyalgia. Basically, the disclosed therapeutic agent was created on the basis of experiments showing improvement in symptoms when etanercept was administered to patients suffering from fibromyalgia. Etanercept is known as a therapeutic agent for rheumatoid arthritis, and the JFIQ score of patients not suffering from fibromyalgia improved considerably in the preferred embodiment. In other words, a therapeutic agent for fibromyalgia is disclosed that contains etanercept as an active ingredient in an effective amount.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.